pyrazines has been researched along with Sarcoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gogal, RM; Laver, T; Lee, BM | 1 |
| Algéo, MP; Chaire, V; Italiano, A; Laroche-Clary, A; Le Loarer, F; Malykh, A; Verbeke, S | 1 |
| Driessen, C; Gogel, J; Hartmann, JT; Koscielniak, E; Kraus, M; Malenke, E; Müller, H; Ovaa, H; Overkleeft, H; Rückrich, T | 1 |
| De Becker, A; De Raeve, H; Van Camp, B; Van Riet, I; Vanderkerken, K; Xu, S | 1 |
| Birdsell, CA; Crosby, NA; Ernstoff, MS; Poklepovic, A; Ramakrishnan, V; Roberts, JD; Winning, M; Youseffian, L; Youssefian, LE | 1 |
| von Mehren, M | 1 |
| Antonescu, CR; Kraft, AS; Maki, RG; Scheu, K; Schwartz, GK; Wadler, S; Wright, JJ; Yamada, J | 1 |
| Benjamin, RS; Burgess, MA; Gray, R; Jenkins, J; Papadopolous, NE; Patel, SR; Plager, C; Sidhu, G | 1 |
1 review(s) available for pyrazines and Sarcoma
| Article | Year |
|---|---|
New therapeutic strategies for soft tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2003 |
3 trial(s) available for pyrazines and Sarcoma
| Article | Year |
|---|---|
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Melanoma; Middle Aged; Pyrazines; Radiography; Sarcoma; Treatment Outcome; Young Adult | 2013 |
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2005 |
Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carbamates; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pyrazines; Pyridines; Sarcoma; Treatment Outcome | 1998 |
4 other study(ies) available for pyrazines and Sarcoma
| Article | Year |
|---|---|
Bortezomib inhibits the proteasome, leading to cell death via apoptosis in feline injection site sarcoma cells in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cat Diseases; Cats; Cell Line, Tumor; Proteasome Endopeptidase Complex; Pyrazines; Sarcoma | 2022 |
ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; DNA Damage; Female; Humans; Isoxazoles; Mice; Mice, Knockout; Neoplasm Proteins; Pyrazines; S Phase Cell Cycle Checkpoints; Sarcoma; Telomere Homeostasis; Xenograft Model Antitumor Assays | 2020 |
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Drug Screening Assays, Antitumor; Endoplasmic Reticulum; G2 Phase; Humans; Neoplasm Proteins; Proteasome Inhibitors; Protein Biosynthesis; Protein Folding; Protein Subunits; Pyrazines; Ritonavir; Sarcoma | 2008 |
In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.
Topics: Animals; Antigens, CD34; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Female; Hydroxamic Acids; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Pyrazines; Receptors, Notch; Sarcoma; Vorinostat; Wnt Proteins | 2012 |